Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms
Amgen’s MariTide achieved up to 20% weight loss in a mid-stage trial, but analysts were expecting up to 25%.
Amgen’s MariTide achieved up to 20% weight loss in a mid-stage trial, but analysts were expecting up to 25%.
